Aster DM Healthcare cash flow

Latest FY26

Cash from operations: ₹656cr+54.3% on FY25
Capital spending: ₹478cr+33.9% on FY25
Free cash flow: ₹178cr+161.1% on FY25
Cash from financing: −₹304cr−₹6,358 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	264	255	988	780
	—	0.0	0.2	149	170
	—	123	127	411	329
	—	−103	−127	−4.8	−2.7
	—	0.0	0.0	0.0	−0.3
	—	−1.9	0.8	0.0	0.0
	—	0.0	0.0	7.4	0.7
	—	20.6	18.5	49.7	−5.8
	—	1.9	−7.0	0.0	0.0
	—	0.0	−76.9	0.0	0.0
	—	1.2	18.2	−303	−193
	—	−61.7	−34.5	−222	−318
	—	−96.0	−33.2	0.0	0.0
	—	0.0	0.0	−1,699	−178
	—	61.5	−91.0	0.0	0.0
	—	0.0	0.0	553	777
Cash from operating activities
	551	607	490	273	534
	—	209	49.6	−43.5	1,359
	—	816	540	229	1,893
	—	160	115	71.3	59.0
	—	656	425	158	1,834
Cash from investing activities
	—	469	346	797	717
	—	8.4	10.7	8.7	131
	—	0.7	1.9	46.9	9.2
	—	3.1	7.9	0.0	0.0
	—	0.0	0.0	0.0	16.8
	—	0.0	7,563	0.0	0.0
	—	0.0	73.5	0.0	114
	—	0.0	0.0	−135	0.0
	—	0.0	0.0	0.3	0.3
	—	67.8	64.4	1.3	1.9
	—	124	−1,177	8.0	−4.6
	—	−288	6,015	−885	−972
Cash from financing activities
	—	2.5	0.0	0.0	0.0
	—	0.0	3.1	0.0	0.0
	—	0.0	13.8	0.0	0.0
	—	81.9	0.0	0.0	141
	—	165	188	1,807	357
	—	150	217	0.0	602
	—	131	114	481	445
	—	53.2	56.7	210	149
	—	55.1	6,175	17.9	27.3
	—	0.0	0.0	−44.9	189
	—	−304	−6,358	1,053	−817
	—	63.4	82.1	326	44.7
	—	0.1	0.3	6.4	21.0
	—	63.5	82.4	332	65.7
	—	—	165	697	365
Reference items
	958	901	765	578	1,565
	19.6%	19.4%	18.5%	15.6%	13.1%
	178	178	68.3	−648	986
	—	184	−15.5	−2,476	—
	₹3.44	₹3.44	₹1.32	−₹12.50	₹19.03
	197.26×	—	—	—	—
	—	1.54×	0.08×	0.75×	3.86×
	—	160	115	71.3	59.0
	—	53.2	56.7	210	149

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTERDM₹679.20

Aster DM Healthcare Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH KIMS COHANCE WOCKPHARMA SYNGENE GLAND LALPATHLABMcap ₹35,191 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	780.4	987.8	254.7	264.3	—
+ Impairment Loss / (Reversal)	169.6	148.8	0.2	0.0	—
+ Finance Costs	329.2	410.8	127.0	123.0	—
+ Interest Income	-2.7	-4.8	-127.0	-103.3	—
+ Dividend Income	-0.3	0.0	0.0	0.0	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.8	-1.9	—
+ Share-based Payments	0.7	7.4	0.0	0.0	—
+ Other Non-cash Items	-5.8	49.7	18.5	20.6	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-7.0	1.9	—
+ Other Reconciling Items	0.0	0.0	-76.9	0.0	—
Changes in Working Capital
+ Inventories	-193.0	-303.0	18.2	1.2	—
+ Trade Receivables — Current	-318.5	-221.9	-34.5	-61.7	—
+ Other Financial Assets — Non-current	0.0	0.0	-33.2	-96.0	—
+ Other Current Assets	-177.9	-1,699.1	0.0	0.0	—
+ Other Financial Liabilities — Current	0.0	0.0	-91.0	61.5	—
+ Other Current Liabilities	777.3	552.7	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	533.9	272.5	490.0	606.7	551.0
+ Total Adjustments (incl. Working Capital)	1,359.1	-43.5	49.6	209.5	—
Cash from Operations (pre-tax)	1,892.9	229.1	539.6	816.1	—
+ Income Taxes Paid	59.0	71.3	114.5	160.2	—
Cash from Operating Activities	1,834.0	157.8	425.1	655.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	717.2	796.9	346.0	469.1	—
+ Acq of Intangible Assets	131.0	8.7	10.7	8.4	—
+ Disp of Fixed Assets	9.2	46.9	1.9	0.7	—
+ Purchase of Investments (Equity / Debt)	0.0	0.0	7.9	3.1	—
+ Acq of Subsidiaries / Businesses (net)	16.8	0.0	0.0	0.0	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	7,563.2	0.0	—
+ Loans & Advances Made	113.7	0.0	73.5	0.0	—
+ Loans & Advances Repaid	0.0	-135.4	0.0	0.0	—
+ Dividends Received — Investing	0.3	0.3	0.0	0.0	—
+ Interest Received — Investing	1.9	1.3	64.4	67.8	—
+ Other Inflows / (Outflows) — Investing	-4.6	8.0	-1,176.5	123.9	—
Cash from Investing Activities	-971.9	-884.7	6,014.9	-288.2	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	2.5	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	3.1	0.0	—
+ Proceeds — Change in Ownership of Subsidiaries	0.0	0.0	13.8	0.0	—
+ Payments — Change in Ownership of Subsidiaries	140.8	0.0	0.0	81.9	—
+ Proceeds from Borrowings	357.5	1,806.8	188.5	165.0	—
+ Repayment of Borrowings	601.8	0.0	216.7	150.4	—
+ Payment of Lease Liabilities	445.3	481.2	114.5	131.2	—
+ Interest Paid	149.0	210.0	56.7	53.2	—
+ Dividends Paid	27.3	17.9	6,175.3	55.1	—
+ Other Inflows / (Outflows) — Financing	189.3	-44.9	0.0	0.0	—
Cash from Financing Activities	-817.4	1,052.8	-6,357.8	-304.3	—
Net Changes in Cash (pre-FX)	44.7	326.0	82.1	63.4	—
+ Effect of FX Rate Changes on Cash	21.0	6.4	0.3	0.1	—
Net Changes in Cash	65.7	332.4	82.4	63.5	—
Closing Cash	365.1	697.5	164.6	—	—
Reference Items
EBITDA	1,565.3	578.0	764.5	901.0	958.0
EBITDA Margin %	13.12	15.62	18.47	19.41	19.65
Free Cash Flow (CFO − Capex)	985.8	-647.8	68.3	178.4	178.4
Free Cash Flow to Equity	—	-2,475.9	-15.5	184.2	—
Free Cash Flow per Basic Share	19.03	-12.50	1.32	3.44	3.44
Price to Free Cash Flow	—	—	—	—	197.26
Cash Flow to Net Income	3.86	0.75	0.08	1.54	—
Cash Paid for Taxes	59.0	71.3	114.5	160.2	—
Cash Paid for Interest	149.0	210.0	56.7	53.2	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.